Urinary bladder cancer is a relatively common condition. A significant proportion of intermediate and highly malignant tumors recur and progress to invasive cancer. Various pharmaceutical agents have been tested in different regimens of intravesical treatment to prevent recurrence and progression. Currently, the standard treatment for non-invasive bladder cancers is the immediate, -after complete tumor resection- injection of a chemotherapeutic agent. For patients at intermediate-risk, a series of intravesical chemotherapy or immunotherapy for a 6-week period is suggested.

Intravesical installation of pharmaceutical agents to prevent recurrence and progression of superficial bladder cancer.

Perletti, Gianpaolo
Membro del Collaboration Group
2020-01-01

Abstract

Urinary bladder cancer is a relatively common condition. A significant proportion of intermediate and highly malignant tumors recur and progress to invasive cancer. Various pharmaceutical agents have been tested in different regimens of intravesical treatment to prevent recurrence and progression. Currently, the standard treatment for non-invasive bladder cancers is the immediate, -after complete tumor resection- injection of a chemotherapeutic agent. For patients at intermediate-risk, a series of intravesical chemotherapy or immunotherapy for a 6-week period is suggested.
2020
Bladder cancer, superficial tumors, intravesical treatment, complementary local therapy
Stamatiou, Konstantinos; Perletti, Gianpaolo
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2097204
 Attenzione

L'Ateneo sottopone a validazione solo i file PDF allegati

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact